biostudies-literatureLu JBasic and Applied Basic Research Foundation of Guangdong Provincethe Scientific and Technological Planning Project of Guangzhou City37https://www.ebi.ac.uk/biostudies/studies/S-EPMC11853526biostudies-literatureUnknown18(1)<h4>Background</h4>m6A methylation modification is a new regulatory mechanism involved in tumorigenesis and tumor-immunity interaction. However, its impact on glioma immune microenvironment and clinical outcomes remains unclear.<h4>Methods</h4>Comprehensive expression profiles of 18 m6A regulators were used to identify molecular subtypes exhibiting distinct m6A modification patterns in 1673 glioma samples sourced from public datasets. A multi-genes signature was constructed for predicting clinical outcomes and response to immunotherapy in glioma patients. Immunohistochemistry and cellular experiments were performed for validation.<h4>Results</h4>Two m6A subtypes of gliomas were identified. The m6A-low-risk subtype was characterized by paucity of immune infiltrates; While the m6A-high-risk BMC medical genomicsm6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas.PMC118535262022010105152022A15151111182023A04J1782Li DHu WLu JSai KChen SJiang Pfalsem6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas.<h4>Background</h4>m6A methylation modification is a new regulatory mechanism involved in tumorigenesis and tumor-immunity interaction. However, its impact on glioma immune microenvironment and clinical outcomes remains unclear.<h4>Methods</h4>Comprehensive expression profiles of 18 m6A regulators were used to identify molecular subtypes exhibiting distinct m6A modification patterns in 1673 glioma samples sourced from public datasets. A multi-genes signature was constructed for predicting clinical outcomes and response to immunotherapy in glioma patients. Immunohistochemistry and cellular experiments were performed for validation.<h4>Results</h4>Two m6A subtypes of gliomas were identified. The m6A-low-risk subtype was characterized by paucity of immune infiltrates; While the m6A-high-risk 2025-01-01T00:00:00Z2025 Feb2025-04-03T23:44:21.99Z2025-04-03T23:44:21.99ZS-EPMC118535263999480010.1186/s12920-025-02104-9